William Audeh

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer

Melinda L. Telli, Jessica A. Hellyer, William Audeh et al. · Breast Cancer Research and Treatment · 2017 · 133 citations

Medicine, Genetics, Oncology +13

HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles

Huina Zhang, Hani Katerji, Bradley M. Turner et al. · Modern Pathology · 2022 · 108 citations

Medicine, Oncology, Pathology +16

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial

Hatem Soliman, Varsha Shah, Gordan Srkalović et al. · BMC Cancer · 2020 · 64 citations · Full text

Medicine, Oncology, Breast Oncology +16

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

Michaela L. Tsai, Shelly S. Lo, William Audeh et al. · JAMA Oncology · 2017 · 47 citations · Full text

Medicine, Biostatistics, Oncology +14